Marlio Charles Mosseri, a 10% owner of Nuvectis Pharma, Inc. (NASDAQ:NVCT), acquired 50,000 shares of common stock for a total value of $916,000 on June 30, 2026. The shares were purchased at a weighted average price of $18.32 per share, with individual transaction prices ranging from $18.29 to $18.32. The insider purchase comes as the stock trades at $19.75, down sharply from its previous close of $28.53. According to InvestingPro analysis, the stock is currently overvalued relative to its Fair Value, despite the recent 25% weekly decline. An InvestingPro Tip notes the stock has taken a big hit over the last week, though it has delivered a 152% return over the past year.
The acquisition was made indirectly through Emerald Hill Ventures SARL SPF, an entity for which Mr. Mosseri is the beneficial owner. Following this transaction, Mr. Mosseri beneficially owns 3,186,576 shares of Nuvectis Pharma common stock indirectly. Additionally, he directly holds 109,321 shares of common stock.
In other recent news, Nuvectis Pharma announced the pricing of a $100 million public offering, selling 5,000,000 shares of common stock at $20.00 per share. This offering represents a significant 30% discount compared to the previous closing price of $28.53. Following this announcement, Nuvectis Pharma’s stock experienced a notable decline. The company has also provided underwriters with a 30-day option to purchase up to 750,000 additional shares at the same offering price.
Additionally, H.C. Wainwright has raised its price target for Nuvectis Pharma to $39 from $13, while maintaining a Buy rating. This adjustment is attributed to the inclusion of NXP100 and NXP200 in the firm’s valuation model. H.C. Wainwright now forecasts a 55% probability of success for NXP100, based on positive pivotal data from China and a submitted marketing authorization application. These developments reflect the company’s recent strategic financial and research decisions.